Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

If you have alopecia areata, you are probably no stranger to a roller coaster of emotions. It’s true that this condition isn’t life-threatening and doesn't cause physical pain. But it can impact how ...

Alopecia areata is an autoimmune disease that causes hair loss. Although there are several treatment options available for alopecia areata, not all of them are effective, which can be frustrating and ...

Alopecia areata is a type of hair loss that happens when your immune system attacks your hair follicles — “alopecia” means hair loss. But not all types of alopecia are autoimmune related. “Alopecia ...